adebrelimab + paclitaxel + lobaplatin + fluorouracil

This is a combination regimen consisting of four agents: - **Adebrelimab** is a monoclonal antibody targeting PD-L1, functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. - **Paclitaxel** is a taxane-class chemotherapeutic agent that stabilizes microtubules, inhibiting cell division and inducing apoptosis in rapidly dividing cancer cells[1][3][4][5]. - **Lobaplatin** is a third-generation platinum-based chemotherapy drug that forms DNA crosslinks, leading to inhibition of DNA replication and transcription, ultimately causing cell death. - **Fluorouracil (5-FU)** is an antimetabolite chemotherapeutic agent that inhibits thymidylate synthase, disrupting DNA synthesis and function. This combination leverages both immunotherapy (adebrelimab) and multiple cytotoxic mechanisms (paclitaxel, lobaplatin, fluorouracil) for synergistic anti-cancer effects. It has been investigated primarily in the treatment of various solid tumors including esophageal squamous cell carcinoma.